EX-99.2 3 a992ex011822.htm EX-99.2 a992ex011822
Onvansertib Ph 1b/2 mCRC Trial Data Update

 

 
Mark Erlander, Ph.D. Chief Executive Officer

 
20222021 2008 2013 2017

 
20222021 2008 2013 2017

 
• • •

 
1st LINE 2nd LINE

 
2nd LINE HISTORICAL ORR 5% 11.4% 13%

 

 
91.1%

 
Onvansertib DOWNSTREAM S G2 G1 M

 
Katherine Ruffner, MD Chief Medical Officer

 
WEEKS 1−2 WEEKS 3−4

 
WEEKS 1−2 WEEKS 3−4 1 2 3

 
WEEKS 1−2 WEEKS 3−4 HISTORICAL ORR* 5% 11.4% 13% HISTORICAL mPFS* 4.5−5.7 mo 20% ≥6 mo

 
Enrollment*

 
No major/unexpected toxicities GRADE TEAEs* 1 2 3 4 All • • • GRADE TEAEs* 1 2 3 4 All

 
Evaluable Patients Jan 2021 As of Sept 16 As of Dec 3 As of Jan 18 Sept 2021

 
Jan 2021 As of Sept 16 As of Dec 3 As of Jan 18 Sept 2021 Evaluable Patients • Webcast data release • –

 
Jan 2021 As of Sept 16 As of Dec 3 As of Jan 18 Sept 2021 Evaluable Patients 1 2 3 Clinical benefits observed

 

 

 
% c h a n g e in t a rg e t le si o ns f ro m b a se lin e

 
% c h a n g e in t a rg e t le si o n s fr o m b a se lin e % c h a n g e in t a rg e t le si o n s fr o m b a se lin e Patients achieving CR+PR Patients achieving SD

 

 
KRAS Variant CR+PR SD PD Total 6

 
20222021

 

 
Predictive response biomarker • • CR+PR SD PD -100 -50 0 %Change in KRAS MAF Mean CR+PR -96 SD -74 PD -63 ✱ ✱✱

 
• – – – • •

 
CLINICAL PROGRAMS OTHER COMBINATIONS • • •

 
Preclinical IND En. Ph 0/1 Ph 2 Status Partners

 
DNA DAMAGING AGENTS MICROTUBULE TARGETING EPIGENETICS

 

 

 
Learn more at www.CardiffOncology.com